IPO TRACKER

A real-time look at every biotech IPO filed and the amount raised in all the world's indexes. Compiled by editor Max Gelman.

COMPANIES
RAISED
Traditional IPOs

6

1.21B

SPACs

0

0

TOTAL

6

1.21B

IPO Tracker Logo
Explore: 2021|2022|2023
Q1
CG On­col­o­gy
Ar­riVent Bio­Phar­ma
Al­to Neu­ro­science
Fractyl Health
Kyver­na Ther­a­peu­tics
Metageno­mi

PRICED

Metageno­mi

Type & Stage
IPO: Priced
CEO
Brian Thomas
ticker
MGX
exchange
NASDAQ
IPO Date
9 February
Total Raised
$93.75M
Priced at
$15
Current Price
$2.96

snapshot ▲

The gene edit­ing start­up was one of the few pre­clin­i­cal biotechs to go pub­lic in re­cent years as many in­vestors fa­vored lat­er-stage bets dur­ing the down­turn of 2022 and 2023. Metageno­mi has part­ner­ships with Mod­er­na, Affi­ni-T Ther­a­peu­tics and Io­n­is Phar­ma­ceu­ti­cals, and has reeled in blue chip in­vestors in­clud­ing Bay­er, RA Cap­i­tal, No­vo Hold­ings and oth­ers.

coverage

Kyver­na Ther­a­peu­tics

Type & Stage
IPO: Priced
CEO
Peter Maag
ticker
KYTX
exchange
NASDAQ
IPO Date
8 February
Total Raised
$319M
Priced at
$22
Current Price
$8.08

snapshot ▲

The Cal­i­for­nia biotech filed while in Phase II test­ing with its lead CAR-T can­di­date. Kyver­na is one of the biotechs lead­ing cell ther­a­py’s ex­pan­sion be­yond blood can­cer and in­to au­toim­mune dis­eases. The biotech cap­i­tal­ized on the mo­ment by go­ing pub­lic in ear­ly Feb­ru­ary.

Kyver­na Ther­a­peu­tics files for IPO as au­toim­mune CAR-T space heats up
Ex­clu­sive: Au­toim­mune CAR-T biotech Kyver­na Ther­a­peu­tics is con­sid­er­ing an IPO next month

coverage

Fractyl Health

Type & Stage
IPO: Priced
CEO
Harith Rajagopalan
ticker
GUTS
exchange
NASDAQ
IPO Date
2 February
Total Raised
$110M
Priced at
$15
Current Price
$3.49

snapshot ▲

The Mass­a­chu­setts biotech is work­ing on an en­do­scop­ic pro­ce­dur­al ther­a­py for type 2 di­a­betes and obe­si­ty, and caught at­ten­tion for work on a gene ther­a­py in biotech’s most talked-about space: GLP-1. Fractyl ex­pects to start test­ing the gene ther­a­py in pa­tients with type 2 di­a­betes and even­tu­al­ly in obe­si­ty, as well. It’s been a long time com­ing for Fractyl, which dis­closed a $100 mil­lion Se­ries F in June 2021 and filed to go pub­lic short­ly there­after, but the harsh pub­lic mar­ket con­di­tions of the next two years would prove too frigid.

coverage

Al­to Neu­ro­science

Type & Stage
IPO: Priced
CEO
Amit Etkin
ticker
ANRO
exchange
NYSE
IPO Date
2 February
Total Raised
$128.6M
Priced at
$16
Current Price
$12.79

snapshot ▲

Al­to Neu­ro­science went pub­lic as it con­ducts mul­ti­ple mid-stage stud­ies of its lead drugs for ma­jor de­pres­sive dis­or­der. The neu­ro­science field has been buoyed by re­cent multi­bil­lion-dol­lar ac­qui­si­tions, a se­ries of large start­up fi­nanc­ings and an IPO from Neumo­ra. The Cal­i­for­nia biotech has li­censed as­sets from Sanofi, Pal­isade Bio and Ava­lo Ther­a­peu­tics and is run­ning mul­ti­ple clin­i­cal tri­als.

coverage

Ar­riVent Bio­Phar­ma

Type & Stage
IPO: Priced
CEO
Bing Yao
ticker
AVBP
exchange
NASDAQ
IPO Date
26 January
Total Raised
$175M
Priced at
$18
Current Price
$26.72

snapshot ▲

The Penn­syl­va­nia biotech is test­ing an EGFR-tar­get­ed ty­ro­sine ki­nase in­hibitor al­ready ap­proved in Chi­na. Ar­riVent ex­pects da­ta from the late-stage on­col­o­gy tri­al in 2025 and an­tic­i­pates an IPO would help fund pre-com­mer­cial and mar­ket­ing ac­tiv­i­ties. It was formed by Bing Yao, who sold his pre­vi­ous com­pa­ny, Viela Bio, to Hori­zon Ther­a­peu­tics.

coverage

CG On­col­o­gy

Type & Stage
IPO: Priced
CEO
Arthur Kuan
ticker
CGON
exchange
NASDAQ
IPO Date
25 January
Total Raised
$380M
Priced at
$19
Current Price
$36.88

snapshot ▲

CG On­col­o­gy was quick out of the gates in the first week of 2024, be­com­ing the first biotech to file for an IPO as the mar­kets ap­peared poised for an up­turn, and its stock popped 95% in the first day of trad­ing af­ter be­ing twice up­sized. The Phase III biotech is one of mul­ti­ple drug de­vel­op­ers in late-stage de­vel­op­ment for new blad­der can­cer treat­ments. If suc­cess­ful, it ex­pects to file for ap­proval as ear­ly as late 2024. The Cal­i­for­nia biotech start­ed as Cold Genesys in 2010 and had raised a $105 mil­lion crossover in sum­mer 2023. Its tick­er sym­bol stands for “Can­cer Gone.”

coverage

A service from the Financial Times